Andere Sprachen Propanc Biopharma, Inc.

Aktien

A3EEVN

US74346N6022

PPCB

Markt geschlossen - OTC Markets Andere Börsenplätze 21:03:38 03.05.2024			% 5 Tage	% 1. Jan.
0.0008 ^USD	0.00%		-20.00%	-93.33%

16.04.	Propanc Biopharma, Inc. erhält Erteilungsbescheinigung für ?Zusammensetzung von Proenzymen zur Krebsbehandlung? Patent vom Europäischen Patentamt	CI
20.02.	Propanc Biopharma, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Propanc Biopharma : Material Agreement - Form 8-K	22.04.
Propanc Biopharma Receives Certificate of Grant for Composition of Proenzymes for Cancer Treatment Patent from European Patent Office	17.04.
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	16.04.
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	16.04.
Propanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment, an inside Look at Drug Development and Strategic Financing	09.04.
Propanc Biopharma : Material Agreement - Form 8-K	11.03.
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding	01.03.
Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study	23.02.
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	20.02.
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	16.01.
Propanc Biopharma's Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP	14.12.
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding	11.12.
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	04.12.
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14.11.
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding	29.10.23
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding	20.10.23
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC	16.10.23
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC	12.10.23
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28.09.23
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding	31.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Propanc Biopharma, Inc.

Aktien

A3EEVN

US74346N6022

PPCB

Andere Sprachen

Filter